Mather Group LLC. Acquires Shares of 235 Teleflex Incorporated (NYSE:TFX)

Mather Group LLC. bought a new stake in Teleflex Incorporated (NYSE:TFX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 235 shares of the medical technology company’s stock, valued at approximately $59,000.

A number of other hedge funds have also made changes to their positions in the stock. Rowlandmiller & PARTNERS.ADV lifted its stake in Teleflex by 2.0% during the first quarter. Rowlandmiller & PARTNERS.ADV now owns 8,938 shares of the medical technology company’s stock worth $2,022,000 after purchasing an additional 175 shares during the last quarter. Nomura Holdings Inc. bought a new position in Teleflex in the fourth quarter worth about $237,000. PNC Financial Services Group Inc. boosted its stake in Teleflex by 6.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 18,089 shares of the medical technology company’s stock valued at $4,510,000 after acquiring an additional 1,018 shares during the period. Vanguard Group Inc. raised its stake in shares of Teleflex by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,454,016 shares of the medical technology company’s stock valued at $1,359,904,000 after purchasing an additional 57,132 shares in the last quarter. Finally, Wahed Invest LLC lifted its holdings in Teleflex by 8.9% in the fourth quarter. Wahed Invest LLC now owns 798 shares of the medical technology company’s stock worth $199,000 after purchasing an additional 65 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on TFX. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a report on Friday, May 3rd. Truist Financial lowered their price objective on shares of Teleflex from $240.00 to $219.00 and set a “hold” rating on the stock in a research note on Friday, May 3rd. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Teleflex has a consensus rating of “Moderate Buy” and an average target price of $257.29.

Teleflex Stock Performance

Teleflex stock opened at $203.40 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.51 and a quick ratio of 1.41. The company has a market cap of $9.58 billion, a P/E ratio of 32.65, a price-to-earnings-growth ratio of 1.96 and a beta of 1.16. Teleflex Incorporated has a fifty-two week low of $177.63 and a fifty-two week high of $262.97. The firm’s 50 day simple moving average is $208.37 and its 200-day simple moving average is $227.11.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, May 2nd. The medical technology company reported $3.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.14. The company had revenue of $737.80 million during the quarter, compared to analyst estimates of $726.85 million. Teleflex had a return on equity of 14.78% and a net margin of 9.82%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.09 earnings per share. As a group, equities research analysts predict that Teleflex Incorporated will post 13.75 EPS for the current year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Wednesday, May 15th were given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date was Tuesday, May 14th. Teleflex’s dividend payout ratio (DPR) is 21.83%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.